

AMENDMENT

U.S. Appln. No. 10/664,859

IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-60. (Cancelled)

Claim 61. (Currently Amended) An isolated polypeptide comprising:

(i) a Drosophila Legless (dLgs) protein consisting of amino acid 1 to 1464 of SEQ ID NO:123, or

(ii) a polypeptide having at least 90% amino acid sequence identity to said (i), wherein said polypeptide inhibits tcf-driven luciferase activity in colon cancer cells, or

(iii) a fragment of (i) or (ii), wherein said fragment ~~comprises a binding site for an anti-dLgs antibody~~ inhibits tcf-driven luciferase activity in colon cancer cells, or

(iv) a peptide having at least 90% amino acid sequence identity in the evolutionary conserved domain of said (i), wherein said domain is

Xaa Xaa Val Phe Ser Thr Xaa Xaa Ala Asn Lys Xaa
Ala Glu Xaa Val Leu) Xaa Gly Gln Xaa Xaa Thr Ile Xaa
Xaa Xaa His (SEQ ID NO:24), or

(v) a peptide having at least 90% amino acid sequence identity in the evolutionary conserved domain of said (i), wherein said domain is

AMENDMENT

U.S. Appln. No. 10/664,859

Xaa Xaa Leu Xaa Xaa Xaa Gln Xaa Xaa His Arg Glu
Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu
Phe Pro Xaa Xaa Xaa Xaa Xaa Xaa Gly Ala (SEQ ID
NO:25).

Claim 62. (Previously Presented) The isolated protein as claimed in Claim 61, wherein said protein (i) is encoded by a nucleotide molecule having the nucleotide sequence of SEQ ID NO:1.

Claim 63. (Previously Presented) The isolated polypeptide of Claim 61, wherein said fragment has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10.

Claim 64. (Previously Presented) A chimeric molecule comprising the polypeptide of Claim 61 fused to a heterologous polypeptide.

Claim 65. (Previously Presented) The chimeric molecule according to Claim 64, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 66. (Previously Presented) A pharmaceutical composition comprising the polypeptide of Claim 61, and a pharmaceutically acceptable carrier.